FoxP3+T regulatory cells in Rheumatoid arthritis and the imbalance of the Treg/TH17 cytokine axis

Egyptian Rheumatologist

Volumn 37, Issue 1, 2015, Pages 7-15

  Al Zifzaf, Dina S ^a   El Bakry, Samah A ^b   Mamdouh, Rasha ^b   Shawarby, Laila A ^b   Ghaffar, Aisha Y Abdel ^b   Amer, Hanaa A ^b   Alim, Afaf Abd ^b   Sakr, Hossam M ^b   Rahman, Rehab Abdel ^b  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

FoxP3; IL 17; Rheumatoid arthritis; TGF ; TGF IL 17 ratio; Tregs

Indexed keywords

C REACTIVE PROTEIN; CD4 ANTIGEN; CYTOKINE; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; RHEUMATOID FACTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ARTICLE; BLOOD CELL COUNT; BONE EROSION; CLINICAL ARTICLE; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HAND RADIOGRAPHY; HUMAN; MALE; MODIFIED STEINBROCKER SCORING METHOD; MUSCULOSKELETAL DISEASE ASSESSMENT; PRIORITY JOURNAL; REAL TIME ECHOGRAPHY; REAL TIME ULTRASOUND SCANNER; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; TH17 CELL; WRIST RADIOGRAPHY;

EID: 84925095670     PISSN: 11101164     EISSN: 20902433     Source Type: Journal    
DOI: 10.1016/j.ejr.2014.06.004     Document Type: Article

References (51)

1. McInnes I.B., Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011, 365(23):2205-2219.
2. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 2012, 51(Suppl. 5):v3-v11.
3. McInnes I.B., Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007, 7(6):429-442.
4. Wang W., Shao S., Jiao Z., Guo M., Xu H., Wang S. The Th17/Treg imbalance and cytokine environment in peripheral blood of patients with rheumatoid arthritis. Rheumatol Int 2012, 32:887-893.
5. Stelmaszczyk-Emmel A., Jackowska T., Rutkowska-Sak L., Marusak-Banacka M., Wasik M. Identification, frequency, activation and function of CD4+ CD25(high) FoxP3+ regulatory T cells in children with juvenile idiopathic arthritis. Rheumatol Int 2012, 32(5):1147-1154.
6. AlFadhli S. The interleukin-23/interleukin-17 axis and the role of Treg/Th17 cells in rheumatoid arthritis and joint destruction. OA Arthritis 2013, 1(1):5.
7. Williams L.M., Rudensky A.Y. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol 2007, 8(3):277-284.
8. Wan Y.Y., Flavell R.A. 'Yin-Yang' functions of transforming growth factor-beta and T regulatory cells in immune regulation. Immunol Rev 2007, 220:199-213.
9. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299(5609):1057-1061.
10. Mai J., Wang H., Yang X.F. Th 17 cells interplay with Foxp3+ Tregs in regulation of inflammation and autoimmunity. Front Biosci (Landmark Ed) 2010, 15:986-1006.
11. Miossec P. Interleukin-17 in fashion, at last: ten years after its description, its cellular source has been identified. Arthritis Rheum 2007, 56:2111-2115.
12. Ulivieri C., Baldari C.T. T-cell-based immunotherapy of autoimmune diseases. Expert Rev Vaccines 2013, 12(3):297-310.
13. Tran D.Q. TGF-β: the sword, the wand, and the shield of FOXP3 (+) regulatory T cells. J Mol Cell Biol 2012, 4(1):29-37.
14. Chavele K.M., Ehrenstein M.R. Regulatory T-cells in systemic lupus erythematosus and rheumatoid arthritis. FEBS Lett 2011, 585(23):3603-3610.
15. Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D.T., Bingham C.O., et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010, 62:2569-2581.
16. Prevoo M.L., Van't Hof M.A., Kuper H.H., Van Leeuwen M.A., Van de Putte L.B., Van Riel P.L. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48.
17. Wolfe F., Michaud K., Pincus T. Development and validation of the Health Assessment Questionnaire II: a revised version of the Health Assessment Questionnaire. Arthritis Rheum 2004, 50:3296-3305.
18. Rahman P., Gladman D.D., Cook R.J., Zhou Y., Young G., Salonen D.D. Radiological assessment in psoriatic arthritis. Br J Rheumatol 1998, 37(7):760-765.
19. Ellegaard K., Torp-Pedersen S., Terslev L., Danneskiold-Samsoe B., Henriksen M., Bliddal H. Ultrasound colour Doppler measurements in a single joint as measure of disease activity in patients with rheumatoid arthritis - assessment of current validity. Rheumatology (Oxford) 2009, 48:254-257.
20. Rizzo C., Ceccarelli F., Gattamelata A., Vavala C., Valesini G., Iagnocco A. Ultrasound in rheumatoid arthritis. Med Ultrason 2013, 15(3):199-208.
21. Cooles F.A., Isaacs J.D., Anderson A.E. Treg cells in rheumatoid arthritis: an update. Curr Rheumatol Rep 2013, 15(9):352.
22. Marçal J.R., Samuel R.O., Fernandes D., de Araujo M.S., Napimoga M.H., Pereira S.A., et al. T-helper cell type 17/regulatory T-cell immunoregulatory balance in human radicular cysts and periapical granulomas. J Endod 2010, 36(6):995-999.
23. Noack M., Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev 2014, 3(6):668-677.
24. high regulatory T cell population in peripheral blood. Rheumatology (Oxford) 2006, 45:1210-1217.
25. Sempere-Ortells J.M., Pérez-Garcia V., Marin-Alberca G., Peris-Pertusa A., Benito J.M., Marco F.M., et al. Quantification and phenotype of regulatory T cells in rheumatoid arthritis according to disease activity score-28. Autoimmunity 2009, 42:636-645.
26. Samson M., Audia S., Janikashvili N., Ciudad M., Trad M., Fraszczak J., et al. Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum 2012, 64(8):2499-2503.
27. Chen R., Tao Y., Qiu K., Huang W., Huang C., Li J. Association of circulating Treg cells with disease activity in patients with rheumatoid arthritis. Nan Fang Yi Ke Da Xue Xue Bao 2012, 32(6):886-889.
28. Möttönen M., Heikkinen J., Mustonen L., Isomäki P., Luukkainen R., Lassila O. CD4+ CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin Exp Immunol 2005, 140(2):360-367.
29. Toubi E., Kessel A., Mahmudov Z., Hallas K., Rozenbaum M., Rosner I. Increased spontaneous apoptosis of CD4+CD25+ T cells in patients with active rheumatoid arthritis is reduced by infliximab. Ann N Y Acad Sci 2005, 1051:506-514.
30. Li N., Ma T., Han J., Zhou J., Wang J., Zhang J., et al. Increased apoptosis induction in CD4+CD25+ Foxp3+ T cells contributes to enhanced disease activity in patients with rheumatoid arthritis through Il-10 regulation. Eur Rev Med Pharmacol Sci 2014, 18(1):78-85.
31. van Amelsfort J.M., Jacobs K.M., Bijlsma J.W., Lafeber F.P., Taams L.S. CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum 2004, 50:2775-2785.
32. Han G.M., O'Neil-Andersen N.J., Zurier R.B., Lawrence D.A. CD4+CD25high T cell numbers are enriched in the peripheral blood of patients with rheumatoid arthritis. Cell Immunol 2008, 253(1-2):92-101.
33. Fontenot J.D., Gavin M.A., Rudensky A.Y. FoxP3 programs the development and function of CD4+CD25+ regulatory T-cells. Nat Immunol 2003, 4:330-336.
34. Suzuki K., Setoyama Y., Yoshimoto K., Tsuzaka K., Abe T., Takeuchi T. Decreased mRNA expression of two FOXP3 isoforms in peripheral blood mononuclear cells from patients with rheumatoid arthritis and systemic lupus erythematosus. Int J Immunopathol Pharmacol 2011, 24:7-14.
35. Leipe J., Grunke M., Dechant C., Reindl C., Kerzendorf U., Schulze-Koops H., et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 2010, 62:2876-2885.
36. Rudensky A.Y. Regulatory T cells and Foxp3. Immunol Rev 2011, 241(1):260-268.
37. Koenders M.I., Joosten L.A., Van den Berg W.B. Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis. Ann Rheum Dis 2006, 65(Suppl. 3):iii29-iii33.
38. Ziolkowska M., Koc A., Luszczykiewicz G., Ksiezopolska-Pietrzak K., Klimczak E., Chwalinska-Sadowska H., et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 2000, 164(5):2832-2838.
39. Moran E.M., Mullan R., McCormick J., Connolly M., Sullivan O., Fitzgerald O., et al. Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies. Arthritis Res Ther 2009, 11(4):R113.
40. Kokkonen H., Söderström I., Rocklöv J., Hallmans G., Lejon K., Rantapää Dahlqvist S. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum 2010, 62:383-391.
41. Metawi S.A., Abbas D., Kamal M.M., Ibrahim M.K. Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA. Clin Rheumatol 2011, 30(9):1201-1207.
42. Chen D.Y., Chen Y.M., Chen H.H., Hsieh C.W., Lin C.C., Lan J.L. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-á therapy. Arthritis Res Ther 2011, 13:R126.
43. Park J.S., Park M.K., Lee S.Y., Oh H.J., Lim M.A., Cho W.T., et al. TWEAK promotes the production of interleukin-17 in rheumatoid arthritis. Cytokine 2012, 60(1):143-149.
44. Zhang L., Li J.M., Liu X.G., Ma D.X., Hu N.W., Li Y.G., et al. Elevated Th22 cells correlated with Th17 cells in patients with rheumatoid arthritis. J Clin Immunol 2011, 31:606-614.
45. Kim J., Kang S., Kim J., Kwon G., Koo S. Elevated levels of T helper 17 cells are associated with disease activity in patients with rheumatoid arthritis. Ann Lab Med 2013, 33(1):52-59.
46. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004, 22:531-562.
47. Yoshimura A., Wakabayashi Y., Mori T. Cellular and molecular basis for the regulation of inflammation by TGF-beta. J Biochem 2010, 147(6):781-792.
48. Eksioglu-Demiralp E., Direskeneli H., Akoglu T. Levels of serum transforming growth factor-beta1 do not increase in Behçet's disease, in contrast to rheumatoid arthritis. J Rheumatol 1999, 26(4):1010-1011.
49. Mieliauskaite D., Venalis P., Dumalakiene I., Venalis A., Distler J. Relationship between serum levels of TGF-beta1 and clinical parameters in patients with rheumatoid arthritis and Sjögren's syndrome secondary to rheumatoid arthritis. Autoimmunity 2009, 42(4):356-358.
50. Cheon H., Yu S.J., Yoo D.H., Chae I.J., Song G.G., Sohn J. Increased expression of pro-inflammatory cytokines and metalloproteinase-1 by TGF-β1 in synovial fibroblasts from rheumatoid arthritis and normal individuals. Clin Exp Immunol 2002, 127(3):547-552.
51. Boissier M.C., Assier E., Falgarone G., Bessis N. Shifting the imbalance from Th1/Th2 to Th17/treg: the changing rheumatoid arthritis paradigm. Joint Bone Spine 2008, 75(4):373-375.